[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"countryName\":\"Laos\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":379},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,13,0,[8,40,69,102,137,165,189,218,243,265,289,327,353],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100619537","environment-pathogens-and-host-interactions-in-melioidosis-100619537",false,"NCT07345910","Environment, Pathogens, and Host Interactions in Melioidosis","Decoding the Triad: the Interplay Between Environment, Pathogen, and Host in Melioidosis (DeEPH)","DeEPH","Inclusion criteria for melioidosis patients:\n\n* Age ≥20 years\n* Positive for Burkholderia pseudomallei from any clinical samples\n* Resident of the study area for at least two years, including the follow-up period\n* Willing to participate and give informed consent.\n\nInclusion criteria for healthy controls:\n\n* Age ≥20 years\n* Currently healthy as judged by study doctor\n* Resident of the study area for at least two years, including the follow-up period\n* Willing to participate and give informed consent.\n\nInclusion criteria for sandbox residents:\n\n* Age ≥20 years\n* Resident of the study area for at least two years, including the follow-up period\n* Willing to participate and give informed consent.\n\nExclusion criteria for melioidosis patients:\n\n* Current tuberculosis (TB) or TB treatment within the past six months\n* Documented HIV infection or use of immunosuppressive therapy in the past 12 months\n\nExclusion criteria for healthy controls:\n\n* History of melioidosis\n* Significant acute illness\n* Current fever or soft tissue infection\n\nExclusion criteria for sandbox residents\n\n-N\u002FA",true,"ALL","20 Years",{"count":21,"type":22},2400,"ESTIMATED","OBSERVATIONAL","This is a longitudinal, multicentre observational study conducted across three established microbiology units integrated within hospital and community health systems in Thailand, Lao PDR, and Cambodia.\n\nThe hospital cohort will enroll approximately1,000 patients with positive melioidosis. Participants will be followed at six time points from admission through one year (post-discharge) to capture acute and recovery-phase outcomes, with clinical data collected on demographics, comorbidities, exposures, treatment, adherence, and outcomes.\n\nFor each confirmed case, a healthy control will be recruited within two weeks and matched by age, sex, and village of residence. Controls with no symptoms or history of melioidosis will provide a single blood sample at enrolment and will be followed by telephone at 6 and 12 months.\n\nIn addition to hospital-based surveillance, a high-risk community in northern Ubon Ratchathani-referred to as the Sandbox Village-will be intensively monitored to capture subclinical infections and to assess environmental factors influencing disease acquisition.\n\nThis study is funded by the Wellcome Trust. The grant reference number is 323077\u002FZ\u002F24\u002FZ",[26],"Melioidosis","NOT_YET_RECRUITING","2026-08-07",{"date":30,"type":31},"2026-08-10","ACTUAL",{"date":33,"type":22},"2026-08-01",{"date":35,"type":22},"2034-12-01",{"name":37,"class":38},"University of Oxford","OTHER",3,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":18,"minAge":48,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":52,"phases":53,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":68},"100613148","phase-2-efficacy-and-safety-of-ascending-doses-of-arpraziquantel-in-children-infected-with-opisthorchis-viverrini-100613148","NCT07262814","Efficacy and Safety of Ascending Doses of Arpraziquantel in Children Infected With Opisthorchis Viverrini","Efficacy, Safety and Acceptability of Ascending Doses of Arpraziquantel for Opisthorchis Viverrini Infections in Children Aged 6-7 Years: A Single-blind Randomized Dose-ranging Trial","ADORA-VI","Inclusion Criteria:\n\n* Aged 6 to 7 years (i.e., 72 to 95 months).\n* Written informed consent signed by parents\u002Fcaregivers (signature or thumbprint).\n* Agree to comply with study procedures, including provision of two stool samples at baseline and at follow-up assessment 21-28 days after treatment, respectively.\n* Willing to be examined by a study physician prior to treatment.\n* At least two slides of the quadruple Kato-Katz thick smears positive for O. viverrini.\n\nExclusion Criteria:\n\n* Presence or signs of major systemic illness, e.g. severe anaemia (haemoglobin level of \\\u003C 80 g\u002FL according to WHO) upon initial clinical assessment.\n* Known or suspected infection with Taenia solium (cysticercosis).\n* Known or suspected acute schistosomiasis.\n* Abnormal liver and kidney function.\n* Use of anthelminthic drugs within 4 weeks before or during study period.\n* Known allergy to study medications (i.e. praziquantel or any of the excipients).\n* Being prescribed or taking concomitantly medication with known contraindication or drug interactions with the study medication.\n* Concurrent participation in other clinical trials.","6 Years","7 Years",{"count":51,"type":22},125,"INTERVENTIONAL",[54],"PHASE2","This study aims to assess the efficacy, safety and acceptability of ascending doses of arpraziquantel in children infected with Opisthorchis viverrini. The primary objective is to determine the dose-response relationship in terms of cure rate. This study will involve children aged 6-7 years, since O. viverrini infections often occur in pre-school and school-aged children, and this group is largely left untreated in current public health programs.",[57],"Opisthorchis Viverrini","RECRUITING","2026-08-02",{"date":61,"type":31},"2026-08-04",{"date":63,"type":31},"2026-07-22",{"date":65,"type":22},"2026-10",{"name":67,"class":38},"Jennifer Keiser",1,{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":75,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":18,"minAge":77,"maxAge":4,"enrollmentInfo":78,"targetDuration":4,"studyType":52,"phases":80,"briefSummary":82,"conditions":83,"keywords":86,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":101},"100594066","smoking-cessation-program-for-lao-people-with-hiv-100594066","NCT07014605","Smoking Cessation Program for Lao People With HIV","Implementing Sustainable Mobile Health Technology to Optimize Smoking Cessation Program for Lao People With HIV","I-STOP","Inclusion Criteria:\n\n1. aged ≥18 years\n2. reachable within 30 days of the target assessment date by different methods (up to 4 phone calls on different days and times, 3 text messages for each platform \\[e.g., SMS, Telegram, or WhatsApp\\], 3 emails if applicable, and via direct contact at a prescheduled clinic appointment if applicable)\n3. consenting to be contacted after 6 months of enrollment and able to provide written informed consent to participate.\n\nExclusion Criteria:\n\n* None.","18 Years",{"count":79,"type":22},1200,[81],"NA","Tobacco use remains the leading modifiable risk factor for preventing cancer globally, particularly among people with HIV (PWH). In Laos, 61-80% of male PWH and 3-10% of female PWH smoke cigarettes. PWH who smoke in Laos have no reliable smoking cessation support. Thus, implementing sustainable and evidence-based smoking cessation interventions for PWH in Laos is needed. The investigators developed a scalable and affordable mHealth-based automated treatment program (MAP) to support Lao and Cambodian smokers to quit smoking. MAP involves interactive, tailored, personalized content (text messages, photos, and videos) delivered via a smartphone app. Along with effective cessation treatments, it is imperative to implement procedures to identify patients who smoke and to connect them to treatment. Our team pioneered the Ask-Advise-Connect (AAC, asking patients about smoking at every visit, briefly advising those who smoke to quit, and connecting them to treatment) approach, which showed great impact in our previous US studies. The purpose of this study is to compare 2 smoking cessation implementation strategies in 8 antiretroviral therapy (ART) clinics in the 6 most populous regions in Laos, using a hybrid type-2 pragmatic effectiveness-implementation study and a parallel cluster randomized trial design. Specifically, the investigators will compare an AAC approach paired with our previously developed MAP (AA-MAP) to an AAC approach paired with less resource-intensive printed self-help material (AA-SH). The investigators will use the Practical, Robust Implementation and Sustainability Model (PRISM), which expands the RE-AIM (Reach, Effectiveness, Adoption, Implementation, and Maintenance) framework to include more contextual factors relevant to program implementation. Aim 1 is to evaluate the reach and effectiveness of AA-MAP versus AA-SH. Reach is the proportion of PWH who smoke and are willing to make a quit attempt that enroll in treatment. Effectiveness is the proportion of enrolled participants who achieve biochemically confirmed point prevalence abstinence 6 months after enrollment. The investigators will also estimate the real-world impact (impact = reach × effectiveness) of each intervention. Aim 2 is to determine other implementation outcomes of AA-MAP and AA-SH. Aim 3 is to assess the resource use and costs of implementing AA-MAP and AA-SH. The project has the potential to transform HIV care and to reduce tobacco-related cancers and other morbidities.",[84,85],"Smoking Cessation","HIV",[87,88,89,90,91],"smoking cessation","cancer control","implementation science","low- and middle-income countries","mobile health","2026-07-28",{"date":94,"type":31},"2026-07-30",{"date":96,"type":22},"2026-08",{"date":98,"type":22},"2029-07-31",{"name":100,"class":38},"University of Oklahoma",2,{"id":103,"slug":104,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":108,"eligibilityCriteria":109,"healthyVolunteers":11,"sex":18,"minAge":110,"maxAge":4,"enrollmentInfo":111,"targetDuration":4,"studyType":52,"phases":113,"briefSummary":115,"conditions":116,"keywords":118,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":136},"100416617","phase-4-southeast-asia-dose-optimization-of-tafenoquine-100416617","NCT04704999","Southeast Asia Dose Optimization of Tafenoquine","Optimizing the Dose of Tafenoquine for the Radical Cure of Plasmodium Vivax Malaria in Southeast Asia","SEADOT","Inclusion Criteria:\n\n* Patients with symptomatic P. vivax mono-infection as diagnosed by microscopy\n* Fever or history of fever in the previous 7 days\n* Quantitative G6PD activity ≥70% of the population median\n* Weight \\>10 kg and ≥2 years old\n* Ability to understand the study instructions and provide written informed consent.\n* Willing to be followed for 4 months\n\nExclusion Criteria:\n\n* Pregnancy\n* Lactation\n* Hb \\\u003C 8 g\u002FdL\n* Severe malaria\n* Blood transfusion in the last 4 months\n* History of allergic response to an 8-aminoquinoline or the nationally recommended schizonticide (e.g., chloroquine, artemether-lumefantrine)\n* Any previous history of a haemolytic event Presence of any condition which in the judgement of the investigator would place the patient at undue risk or interfere with the results of the study (e.g. chronic disease, medications that potentiate or inhibit CYP2D6 or CYP2C8 isoenzyme function)","2 Years",{"count":112,"type":22},820,[114],"PHASE4","Tafenoquine was recently approved by regulatory authorities in the USA and Australia. Tafenoquine is an alternative radical curative treatment to primaquine acting against the dormant liver stage of Plasmodium vivax (the hypnozoite). Tafenoquine (an 8-aminoquinoline) has the substantial advantage of single dosing as compared to a 14-day course of primaquine to achieve radical cure. The recommended tafenoquine dose is 300 mg, which was shown to be significantly worse in radical curative efficacy to a total primaquine dose of 3.5 mg\u002Fkg in Southeast Asia. The cure rate of tafenoquine 300 mg in Southeast Asian study sites was only 74%. The comparator 3.5 mg\u002Fkg total primaquine dose is the standard and most commonly used dose globally, but in Southeast Asia and the Western Pacific, higher doses of primaquine are needed for radical cure. This study aims to determine the optimal dose of tafenoquine in Southeast Asia.\n\nAddendum for Indonesia: The INSPECTOR trial results showed that tafenoquine 300mg was not efficacious for radical cure (79% probability for recurrence after treatment). The comparator arm, low-dose primaquine 3.5mg\u002Fkg divided equally over 14 days, showed a 48% probability of recurrence after treatment). The standard of care for radical cure in Indonesia is high-dose primaquine 7mg\u002Fkg divided in 7 daily doses).",[117],"Plasmodium Vivax Malaria",[119,120,121,122,123,124,125,126,127],"Plasmodium vivax","Relapse","8-aminoquinoline","Tafenoquine","Radical cure","Drug efficacy","Adults","Pediatrics","Primaquine","2026-07-27",{"date":130,"type":31},"2026-07-29",{"date":132,"type":31},"2024-07-22",{"date":134,"type":22},"2028-02-07",{"name":37,"class":38},6,{"id":138,"slug":139,"hasResults":11,"nctId":140,"briefTitle":141,"officialTitle":142,"acronym":143,"eligibilityCriteria":144,"healthyVolunteers":11,"sex":18,"minAge":77,"maxAge":145,"enrollmentInfo":146,"targetDuration":4,"studyType":52,"phases":148,"briefSummary":149,"conditions":150,"keywords":153,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":157,"startDateStruct":159,"completionDateStruct":161,"leadSponsor":163,"locationsCount":164},"100489079","phase-2-a-phase-2-trial-comparing-antiviral-treatments-in-early-symptomatic-influenza-100489079","NCT05648448","A Phase 2 Trial Comparing Antiviral Treatments in Early Symptomatic Influenza","ADaptive ASsessment of TReatments for influenzA: A Phase 2 Multi-centre Adaptive Randomised Platform Trial to Assess Antiviral Pharmacodynamics in Early Symptomatic Influenza Infection (AD ASTRA)","AD ASTRA","Inclusion Criteria:\n\n* Patient understands the procedures and requirements and is willing and able to give informed consent for full participation in the study\n* Adults, male or female, aged 18 to 60 years at time of consent.\n* Early symptomatic Influenza (A or B); at least one reported symptom of influenza (including fever, history of fever, myalgias, headache, cough, fatigue, nasal congestion, rhinorrhoea and sore throat) within 4 days (96 hours)\n* Influenza positive by rapid antigen test OR a positive RT-PCR test for influenza viruses within the last 24hrs with a Ct value of \\\u003C30\n* Able to walk unaided and unimpeded in activities of daily living (ADLs)\n* Agrees and is able to adhere to all study procedures, including availability and contact information for follow-up visits\n\nExclusion Criteria:\n\nThe patient may not enter the study if ANY of the following apply:\n\n* Taking any concomitant medications or drugs which could interact with the study medications or have antiviral activity\n* Presence of any chronic illness\u002Fcondition requiring long term treatment or other significant comorbidity\n* BMI ≥35 Kg\u002Fm2\n* Clinically relevant laboratory abnormalities discovered at screening\n\n  * Haemoglobin \\\u003C10g\u002FdL\n  * Platelet count \\\u003C100,000\u002FuL\n  * ALT \\> 2x ULN\n  * Total bilirubin \\>1.5 x ULN\n  * eGFR \\\u003C70mls\u002Fmin\u002F1.73m2\n* For females: pregnancy, actively trying to become pregnant or lactation (healthy women on OCP are eligible to join)\n* Contraindication to taking, or known hypersensitivity reaction to any of the proposed therapeutics\n* Currently participating in another interventional influenza or COVID-19 therapeutic trial\n* Clinical evidence of pneumonia- e.g. shortness of breath, hypoxaemia, crepitations (imaging not required)\n* Known to be currently co-infected with SARS-CoV-2 (i.e. confirmed with positive ATK or RT-PCR)\n* Received live attenuated influenza virus vaccine within 3 weeks prior to study entry","60 Years",{"count":147,"type":22},3000,[54],"This trial will use a previously validated platform, to quantitatively assess antiviral effects in low-risk patients with high viral burdens and uncomplicated influenza, to determine in-vivo antiviral activity. In this randomised, open-label, controlled, group sequential, adaptive, platform trial, we will compare the performance of available influenza antivirals, and those with potential activity, relative to the control (no treatment) and each other.\n\nAD ASTRA study is supported by the Wellcome Trust Grant ref: 223195\u002FZ\u002F21\u002FZ through the COVID-19 Therapeutics Accelerator",[151,152],"Influenza","Influenza, Human",[151,154,155],"Phase 2","Antiviral Pharmacodynamics","2026-04-09",{"date":158,"type":31},"2026-04-14",{"date":160,"type":31},"2023-02-22",{"date":162,"type":22},"2027-01-01",{"name":37,"class":38},4,{"id":166,"slug":167,"hasResults":11,"nctId":168,"briefTitle":169,"officialTitle":170,"acronym":171,"eligibilityCriteria":172,"healthyVolunteers":11,"sex":18,"minAge":77,"maxAge":145,"enrollmentInfo":173,"targetDuration":4,"studyType":52,"phases":175,"briefSummary":176,"conditions":177,"keywords":179,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":180,"lastUpdatePostDateStruct":181,"startDateStruct":183,"completionDateStruct":185,"leadSponsor":187,"locationsCount":188},"100442478","phase-2-finding-treatments-for-covid-19-a-trial-of-antiviral-pharmacodynamics-in-early-symptomatic-covid-19-platcov-100442478","NCT05041907","Finding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV)","Finding Treatments for COVID-19: A Phase 2 Multi-centre Adaptive Platform Trial to Assess Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV)","PLATCOV","Inclusion Criteria:\n\n* Patient understands the procedures and requirements and is willing and able to give informed consent for full participation in the study.\n* Previously healthy adults, male or female, aged 18 to 60 years at time of consent with early symptomatic COVID-19\n* SARS-CoV-2 positive by lateral flow antigen test OR a positive PCR test for SARS-CoV-2 within the last 24hrs with a Ct value of less than 25 (all viral targets)\n* Symptoms of COVID-19 (including fever, or history of fever) for less than 4 days (96 hours).\n* Oxygen saturation ≥96% measured by pulse-oximetry at time of screening.\n* Able to walk unaided and unimpeded in ADLs\n* Agrees and is able to adhere to all study procedures, including availability and contact information for follow-up visits\n\nExclusion Criteria:\n\nThe patient may not enter the study if ANY of the following apply:\n\n* Taking any concomitant medications or drugs (see appendix 4)†\n* Presence of any chronic illness\u002F condition requiring long term treatment, or other significant comorbidity (e.g. diabetes, obesity but see appendix 4 for the full list)\n* Laboratory abnormalities discovered at screening (see appendix 4)\n* For females: pregnancy, actively trying to become pregnant, or lactation\n* Contraindication to taking, or known hypersensitivity reaction to any of the proposed therapeutics (see appendix 4)\n* Currently participating in another COVID-19 therapeutic or vaccine trial\n* Evidence of pneumonia (although imaging is NOT required)\n\n  * healthy women on the oral contraceptive pill are eligible to join the study",{"count":174,"type":22},3800,[54],"The trial will develop and validate a platform for quantitative assessment of antiviral effects in low-risk patients with high viral burdens and uncomplicated COVID-19 to determine in-vivo antiviral activity. In this randomized open label, controlled, group sequential adaptive platform trial, we will assess the performance of three distinct types of intervention relative to control (no treatment):\n\nA: Small molecule drugs; B: Monoclonal antibodies; C: Dose finding for the constituent parts of nirmatrelvir\u002Fritonavir\n\nPLATCOV study is supported by the Wellcome Trust Grant ref: 223195\u002FZ\u002F21\u002FZ through the COVID-19 Therapeutics Accelerator.",[178],"COVID-19",[178,154,155],"2026-02-16",{"date":182,"type":31},"2026-02-19",{"date":184,"type":31},"2021-09-30",{"date":186,"type":22},"2027-01",{"name":37,"class":38},7,{"id":190,"slug":191,"hasResults":11,"nctId":192,"briefTitle":193,"officialTitle":194,"acronym":195,"eligibilityCriteria":196,"healthyVolunteers":11,"sex":18,"minAge":77,"maxAge":4,"enrollmentInfo":197,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":198,"conditions":199,"keywords":203,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":209,"lastUpdatePostDateStruct":210,"startDateStruct":212,"completionDateStruct":214,"leadSponsor":216,"locationsCount":136},"100529110","health-systems-and-policy-contexts-of-medical-oxygen-100529110","NCT06169514","Health Systems and Policy Contexts of Medical Oxygen","Understanding the Health Systems and Policy Contexts of Medical Oxygen in Africa and Asia (MOXY-HSP)","MOXY-HSP","Key informants will be selected representing government, non-governmental agencies, professional associations, private sector, and civil society.",{"count":68,"type":22},"This is a mixed-methods program evaluation from a health systems and policy perspective, involving (i) stakeholder analysis, (ii) policy-implementation gap analysis, and (iii) comparative country case studies. This study aims to understand how national oxygen strategies achieve impact at national, and subnational level, across country contexts, at what cost.\n\nThe the investigators seek to:\n\n1. Involve policymakers, implementers (including private sector), and medical oxygen users in identifying challenges and understanding potential solutions to medical oxygen access;\n2. Generate new data on how medical oxygen systems work and can be improved from multiple perspectives;\n3. Draw lessons on medical oxygen that can directly inform national and global practice and policy.\n\nThis study will be conducted in 6 of the 9 countries participating in the Clinton Health Access Initiative (CHAI) led Medical Oxygen Implementation (MOXY) program (Uganda, Nigeria, Rwanda, Liberia, Lao PDR, Cambodia).\n\nKey informants will be selected representing government, non-governmental agencies, professional associations, private sector, and civil society. This study will be completed over 4 years, with timelines varying between country study sites.",[200,201,202],"Hypoxemia","Morality","Pneumonia",[204,205,206,207,208],"Health system","Oxygen","Oxygen systems","Oxygen access","Pulse oximetry","2026-02-04",{"date":211,"type":31},"2026-02-06",{"date":213,"type":31},"2024-07-31",{"date":215,"type":22},"2027-12",{"name":217,"class":38},"Murdoch Childrens Research Institute",{"id":219,"slug":220,"hasResults":11,"nctId":221,"briefTitle":222,"officialTitle":223,"acronym":224,"eligibilityCriteria":225,"healthyVolunteers":11,"sex":18,"minAge":226,"maxAge":4,"enrollmentInfo":227,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":229,"conditions":230,"keywords":232,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":235,"lastUpdatePostDateStruct":236,"startDateStruct":238,"completionDateStruct":240,"leadSponsor":242,"locationsCount":164},"100410787","causes-and-outcomes-of-febrile-illness-in-health-facilities-in-rural-south-and-southeast-asia-100410787","NCT04629053","Causes and Outcomes of Febrile Illness in Health Facilities in Rural South and Southeast Asia","Determining the Causes and Outcomes of Febrile Illness in Health Care Facilities in Rural South and Southeast Asia, as Part of the South and Southeast Asian Community-based Trials Network (SEACTN). Work Package B (WP-B).","SEACTN-WP-B","Inclusion Criteria:\n\n1. The patient and\u002For where relevant their parent\u002Fguardian\u002Fcaretaker is willing and able to give informed consent \u002Fassent for participation in the study;\n2. Aged \\> 28 days (day of birth = Day 1);\n3. Axillary temperature at presentation (≥ 37.5°C (99.5°F) OR \\\u003C 35.5°C (95.9°F)) and no more likely cause than sepsis for hypothermia OR History of fever in the 24 hours prior to presentation;\n4. Onset of illness ≤ 14 days\n\nExclusion Criteria:\n\n1. Accident or trauma is the cause for the patient's presentation;\n2. Presentation ≤ 3 days after routine immunisations\n3. Is currently under follow-up or has been afebrile for less than 72 hours after completion of a follow-up period.\n4. The treating healthcare worker's decision is to send the patient home following initial assessment.","29 Days",{"count":228,"type":22},7200,"This prospective multi-site observational study aims to describe causes and clinical outcomes of acute febrile illness as well as host biomarkers in patients aged \\>28 days residing in rural areas in Laos, Myanmar, Thailand, the Thai-Myanmar border region, and Bangladesh and presenting with acute febrile illnesses (≤ 14 days duration) to participating health facilities.\n\nThis study is funded by the UK Wellcome Trust. The grant reference number is 215604\u002FZ\u002F19\u002FZ",[231],"Acute Febrile Illness",[231,233,234],"Causes","Outcomes","2026-01-08",{"date":237,"type":31},"2026-01-12",{"date":239,"type":31},"2022-06-21",{"date":241,"type":22},"2026-12-01",{"name":37,"class":38},{"id":244,"slug":245,"hasResults":11,"nctId":246,"briefTitle":247,"officialTitle":247,"acronym":248,"eligibilityCriteria":249,"healthyVolunteers":11,"sex":18,"minAge":77,"maxAge":250,"enrollmentInfo":251,"targetDuration":4,"studyType":52,"phases":253,"briefSummary":254,"conditions":255,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":257,"lastUpdatePostDateStruct":258,"startDateStruct":260,"completionDateStruct":262,"leadSponsor":264,"locationsCount":101},"100457179","phase-2-mobile-health-technology-for-personalized-tobacco-cessation-support-in-laos-100457179","NCT05233228","Mobile Health Technology for Personalized Tobacco Cessation Support in Laos","SupportLaos","Inclusion Criteria: (pilot RCT in the R21 Phase and main RCT in the R33 Phase):\n\n1. aged ≥18 years\n2. self-reported current combustible cigarette smokers (smoked at least 100 cigarettes in lifetime and currently smoke ≥1 cigarette\u002Fday)\n3. willing to set a quit date within 2 weeks of study enrollment\n4. able to provide written informed consent to participate\n5. able to read Lao (score ≥4 points on the Rapid Estimate of Adult Literacy in Medicine-Short Form).\n\nExclusion Criteria: (pilot RCT in the R21 Phase and main RCT in the R33 Phase)\n\n1. history of a medical condition that precludes use of NRT\n2. ineligibility to participate based on medical or psychiatric conditions diagnosed by a physician\u002Fclinician\n3. enrollment in another cessation program or current use of other cessation medications.","65 Years",{"count":252,"type":22},500,[54],"In Lao People's Democratic Republic (Lao PDR), 51% of adult men and 7% of adult women smoke tobacco. The development and evaluation of sustainable tobacco cessation interventions suitable for widespread adoption in nations such as Lao PDR are pressing public health needs. To address this need, the investigators propose a project that adapts a theoretically and empirically based mobile health (mHealth) technology to help people quit smoking cigarettes in Lao PDR. This mHealth approach includes a fully automated, interactive, personalized, smartphone-delivered intervention for behavioral treatment, delivered through our Insight™ platform.\n\nThis proposed project for Lao PDR includes 2 main phases. In the R21 Phase, the investigators will use formative research methods to adapt our intervention content to the sociocultural context, language, and communication styles of Laotians. In the subsequent R33 Phase, the investigators will conduct a randomized controlled trial (RCT) to evaluate the efficacy of our mHealth intervention and technology. Adult smokers of both sexes will be recruited through 2 large hospitals: Setthathirath Hospital in Vientiane and Champasak Hospital in Champasak Province. Participants (n=500) will be randomized to 1 of 2 treatment groups: Standard Care (SC; n=250) or Automated Treatment (AT; n=250). SC consists of brief advice to quit smoking delivered by research staff, self-help written materials, and a 2-week supply of NRT (transdermal patches). AT consists of all SC components plus a fully automated smartphone-based treatment program that involves interactive and personalized proactive messages, images, or videos. The primary health outcome of the trial is biochemically confirmed self-reported 7-day point prevalence abstinence 12 months post study enrollment. The project also aims to advance mHealth research capacity in Lao PDR and sustain the US-Lao PDR research network. The project has the potential to transform healthcare services for tobacco cessation treatment throughout the country and, ultimately, to reduce tobacco-induced morbidity and mortality significantly.",[256],"Cigarette Smoking","2025-08-11",{"date":259,"type":31},"2025-08-15",{"date":261,"type":31},"2022-04-27",{"date":263,"type":22},"2026-08-31",{"name":100,"class":38},{"id":266,"slug":267,"hasResults":11,"nctId":268,"briefTitle":269,"officialTitle":270,"acronym":271,"eligibilityCriteria":272,"healthyVolunteers":11,"sex":18,"minAge":77,"maxAge":273,"enrollmentInfo":274,"targetDuration":4,"studyType":52,"phases":276,"briefSummary":277,"conditions":278,"keywords":281,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":282,"lastUpdatePostDateStruct":283,"startDateStruct":285,"completionDateStruct":287,"leadSponsor":288,"locationsCount":101},"100553608","phase-2-assessing-antiviral-treatments-in-early-symptomatic-rsv-100553608","NCT06488300","Assessing Antiviral Treatments in Early Symptomatic RSV","Assessment of Respiratory SYNcytial Virus antivirALs: A Phase 2 Multi-centre Adaptive Randomised Platform Trial For the Assessment of Antiviral Pharmacodynamics in aCute Symptomatic RSV Infection (ARSYNAL-FC)","ARSYNAL-FC","Inclusion Criteria:\n\n* Patient understands the procedures and requirements and is willing and able to give informed consent for full participation in the study\n* Adults, male or female, aged ≥18 to \\\u003C65 years at time of consent\n* Early symptomatic RSV; at least one reported symptom of RSV (including fever, history of fever, myalgias, headache, cough, fatigue, nasal congestion, rhinorrhoea and sore throat) within 4 days (96 hours)\n* RSV positive by rapid antigen test OR a positive RT-PCR test for RSV viruses within the last 24hrs with a Ct value of \\\u003C30\n* Able to walk unaided and unimpeded in activities of daily living (ADLs)\n* Agrees and is able to adhere to all study procedures, including availability and contact information for follow-up visits\n\nExclusion Criteria:\n\nThe patient may not enter the study if ANY of the following apply:\n\n* Taking any concomitant medications or drugs which could interact with the study medications or have antiviral activity\n* Presence of any chronic illness\u002Fcondition requiring long term treatment or other significant comorbidity\n* BMI ≥35 Kg\u002Fm2\n* Clinically relevant laboratory abnormalities discovered at screening\n\n  * Haemoglobin \\\u003C10g\u002FdL (\\\u003C12g\u002FdL for all arms if Ribavirin is in the randomisation)\n  * Platelet count \\\u003C100,000\u002FuL\n  * ALT \\> 2x ULN\n  * Total bilirubin \\>1.5 x ULN\n  * eGFR \\\u003C70mls\u002Fmin\u002F1.73m2\n* For females: pregnancy, actively trying to become pregnant or lactating (women on OCP are eligible to join)\n* Contraindication to taking, or known hypersensitivity reaction to any of the proposed therapeutics\n* Currently participating in another interventional RSV, influenza or COVID-19 therapeutic trial\n* Clinical evidence of pneumonia- e.g., shortness of breath, hypoxaemia, crepitations (imaging not required)\n* Known to be currently co-infected with influenza or SARS-CoV-2 (i.e. confirmed with positive ATK or RT-PCR)\n* Received any RSV vaccine within the last year","64 Years",{"count":275,"type":22},1000,[54],"This trial will use a previously validated platform, to quantitatively assess antiviral effects in low-risk patients with high viral burdens and uncomplicated Respiratory Syncytial Virus (RSV), to determine in-vivo antiviral activity. In this randomised, open-label, controlled, group sequential adaptive platform trial, we will assess and compare the performance of currently licensed interventions (including repurposed drugs) with activity against RSV, and those with potential activity demonstrated in pre-clinical and early clinical studies relative to each-other, and the control (no antiviral treatment).\n\nARSYNAL-FC study is funded by Wellcome Trust Grant ref: 226933\u002FZ\u002F23\u002FZ through the COVID-19 Therapeutics Accelerator",[279,280],"Respiratory Syncytial Virus","Respiratory Syncytial Virus, Human",[279,154,155],"2025-06-27",{"date":284,"type":31},"2025-07-02",{"date":286,"type":31},"2024-07-25",{"date":162,"type":22},{"name":37,"class":38},{"id":290,"slug":291,"hasResults":11,"nctId":292,"briefTitle":293,"officialTitle":294,"acronym":4,"eligibilityCriteria":295,"healthyVolunteers":17,"sex":18,"minAge":296,"maxAge":297,"enrollmentInfo":298,"targetDuration":4,"studyType":52,"phases":300,"briefSummary":301,"conditions":302,"keywords":311,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":318,"lastUpdatePostDateStruct":319,"startDateStruct":321,"completionDateStruct":323,"leadSponsor":325,"locationsCount":68},"100566113","integration-to-improve-adolescent-health-and-hpv-vaccination-in-laos-100566113","NCT06650956","Integration to Improve Adolescent Health and HPV Vaccination in Laos","Integrated Service Delivery to Improve Adolescent Health and HPV Vaccination in Lao PDR: a Quasi-Experimental Mixed-Methods Study","Inclusion Criteria:\n\n* Female aged 10-13 years for HPV vaccination and SRH education\n* Male aged 10-13 years for SRH education\n* 10-13-year-old male and female students in randomly selected schools with at least 100 students in target classes (year-5 primary, year-1, 2 and 3 secondary)\n* 10-13-year-old males and females who are out-of-school and living in 2 remote villages each from four randomly selected health centers located around the selected schools\n\nExclusion Criteria:\n\n* males and females younger than 10 years or older than 13 years","10 Years","13 Years",{"count":299,"type":22},700,[81],"The goal of this study is to find out if adding HPV vaccination to adolescent health services works to increase HPV vaccine uptake in 10-13-year-old girls in Laos. The study will also look at the effects of adding HPV vaccination on the use of other health services in 10-13-year-old boys and girls.\n\nThe main questions the study aims to answer are:\n\n1. Does adding HPV vaccination to adolescent health services increase HPV vaccine uptake in girls aged 10-13 years compared to girls who only receive standard HPV vaccination services?\n2. Does adding HPV vaccination to adolescent health services increase the use of other health services in 10-13-year-old adolescent boys and girls compared to adolescents who only receive standard HPV vaccination services?\n3. What are the barriers and facilitators to using the combined intervention in Laos?\n4. What are the opinions of adolescents, caregivers, healthcare providers, and other stakeholders on the combined intervention?\n5. How much does it cost and how well it works to combine HPV vaccination with adolescent health services, as opposed to providing HPV vaccination alone?\n\nResearchers will compare a combined intervention to standard HPV vaccination services to see if the combined intervention works to increase HPV vaccination uptake and the use of other health services. The combined intervention includes HPV vaccination given at schools, health facilities, and through community outreach. It also includes education on sexual and reproductive health, counseling, and other health services. Participants in the combined intervention group will:\n\n1. Receive the HPV vaccine at school or at a health facility.\n2. Take part in group discussions about sexual and reproductive health.\n3. Take part in individual counseling sessions.\n4. Use other health services as needed.\n\nParticipants in the comparison group will receive standard HPV vaccination services, including:\n\n• HPV vaccination given at schools, health facilities, and through community outreach.",[303,304,305,306,307,308,309,310],"Healthy","Adolescents","Integrated, Community-Health Systems","HPV Vaccines","Sexual and Reproductive Health","Knowledge","Attitude","Health Workers",[312,313,314,315,316,317],"hpv vaccination","adolescent health","integration","lao pdr","cervical cancer prevention","sexual and reproductive health","2025-03-10",{"date":320,"type":31},"2025-03-12",{"date":322,"type":31},"2024-11-01",{"date":324,"type":22},"2025-05",{"name":326,"class":38},"Health Poverty Action",{"id":328,"slug":329,"hasResults":11,"nctId":330,"briefTitle":331,"officialTitle":332,"acronym":333,"eligibilityCriteria":334,"healthyVolunteers":17,"sex":18,"minAge":77,"maxAge":4,"enrollmentInfo":335,"targetDuration":4,"studyType":52,"phases":337,"briefSummary":339,"conditions":340,"keywords":343,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":346,"lastUpdatePostDateStruct":347,"startDateStruct":349,"completionDateStruct":350,"leadSponsor":351,"locationsCount":101},"100513999","phase-2-rickettsia-clearance-study-100513999","NCT05972772","Rickettsia Clearance Study","A Pharmacokinetic-pharmacodynamic Study of Early Rickettsia Clearance in Murine Typhus or Scrub Typhus Patients Treated with Doxycycline or Azithromycin","RiCS","Inclusion Criteria:\n\n* Age above or equal 18 years\n* Able to take oral medication\n* Rapid test positive for murine typhus or scrub typhus\n* Agrees to stay in hospital for at least 36 hours and to attend for scheduled follow up visits\n* Written informed consent to participate in the study\n* A negative urinary pregnancy test for all women of child-bearing age\n\nExclusion Criteria:\n\n* Pregnancy or breast feeding\n* Previous allergic reaction to doxycycline or azithromycin\n* Received more than one dose of chloramphenicol, doxycycline, tetracycline, fluoroquinolones, rifampicin or azithromycin during this hospital admission or more than one dose of any of these drugs in the week before admission\n* Contraindication to doxycycline: severe hepatic impairment, known SLE\n* Contraindication to azithromycin: sever hepatic impairment\n* Severe typhus defined as the presence of one or more of the following:\n\n  1. Reduced level of consciousness\n  2. Clinical jaundice\n  3. Shock (BP systolic \\\u003C80 mmHg)\n  4. Unable to take oral medication\n  5. Radiological evidence of pneumonia\n  6. Clinical evidence for meningitis\u002Fencephalitis or the need of LP\n  7. Alternative diagnosis confirmed that explains the presenting symptoms\n  8. Any other syndrome which in the opinion of the admitting doctor constitutes severe typhus (reason must be stated)",{"count":336,"type":22},72,[54,338],"PHASE3","Murine typhus is a disease caused by Rickettisa typhi, an obligate intracellular bacterium transmitted by rodent fleas. The disease has a worldwide distribution; however the true burden is unknown, related to its non-specific presentation and lack of access to diagnosis in many regions. A systematic review of untreated murine typhus based on observational studies of a total of 239 patients has estimated the mortality associated with the disease at between 0.4% and 3.6%.\n\nScrub typhus is caused by Orientia tsutsugamushi and transmitted by the larval stage of chigger mites (Trombiculidae family). It has been estimated to affect at least one million people each year. A systematic review found varying reports of the mortality associated with untreated scrub typhus ranging from 0-70% (median 6%).\n\nPolymerase chain reaction (PCR) based diagnosis of rickettsial infections is only available in one centre (Mahosot Hospital) in Vientiane. A number of hospitals use a variety of point-of-care antibody tests to diagnose rickettsial infections however many of these have not been validated and they are of uncertain sensitivity and specificity. In 2006 results of a two year prospective study of 427 patients presenting to Mahosot Hospital with a febrile illness and negative blood cultures showed that 115 (27%) patients had an acute rickettsial infection, confirmed by serological testing. Among these patients, 41 were diagnosed with murine typhus and 63 with scrub typhus. Antibacterial agents with activity against rickettsial pathogens include doxycycline, azithromycin, chloramphenicol and rifampicin. Azithromycin is often reserved for pregnant women or children below the age of 8 years due to lasting concerns after the tetracycline-associated staining of growing bones and teeth in the past. Evidence is accumulating that doxycycline is superior to azithromycin for the treatment of rickettsial disease. Clinical treatment failures have occurred following azithromycin treatment of murine typhus. The relationship between rickettsial bacteria load and both disease severity and response to treatment has not been characterised. Rickettsial concentrations in blood are generally low, of the order of 210 DNA copies\u002FmL blood for R. typhi and 284 DNA copies\u002FmL blood for O. tsutsugamushi. At present, there is no standard antibiotic susceptibility testing (AST) method for R. typhi and O. tsutsugamushi. The gold standard method for AST for Rickettsia pathogens is the plaque assay which determines minimal inhibitory concentration (MICs) from the smallest antimicrobial concentration inhibiting rickettsial plaque forming unit formation. This method is laborious and time consuming, taking approximately 14-16 days based on species to yield a result. Molecular detection methods are useful for diagnosing patients infected with rickettsial pathogens and has been applied for antibiotic susceptibility testing. Antibiotic susceptibility testing based on DNA synthesis inhibition detecting by quantitative PCR (qPCR) for O. tsutsugamushi clinical isolates has been reported. However, the relationship between antibiotic susceptibility profiles and treatment response has not been studied. There is a need to develop a reliable ex vivo method to characterize the treatment response and compare susceptibility of R. typhi and O. tsutsugamushi to different agents.",[341,342],"Infectious Disease","Therapeutics",[344,345],"Scrub Typhus","Typhus, Endemic Flea-Borne","2024-12-23",{"date":348,"type":31},"2024-12-27",{"date":322,"type":31},{"date":263,"type":22},{"name":352,"class":38},"Lao-Oxford-Mahosot Hospital Wellcome Trust Research Unit",{"id":354,"slug":355,"hasResults":11,"nctId":356,"briefTitle":357,"officialTitle":358,"acronym":4,"eligibilityCriteria":359,"healthyVolunteers":11,"sex":360,"minAge":361,"maxAge":362,"enrollmentInfo":363,"targetDuration":4,"studyType":52,"phases":365,"briefSummary":366,"conditions":367,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":370,"lastUpdatePostDateStruct":371,"startDateStruct":373,"completionDateStruct":375,"leadSponsor":377,"locationsCount":68},"100566386","can-village-health-volunteersworkers-working-as-male-female-pairs-improve-the-use-of-postnatal-care-services-in-the-lao-peoples-democratic-republic-100566386","NCT06654505","Can Village Health Volunteers\u002FWorkers Working As Male-Female Pairs Improve the Use of Postnatal Care Services in the Lao People's Democratic Republic","Effectiveness of Village Health Volunteers\u002FWorkers Working As Male-Female Pairs on Women's Use of Postnatal Care Services in Sepone District in Lao People's Democratic Republic: a Protocol for a Quasi-experimental Cluster Study","Inclusion Criteria:\n\n* Women who gave birth within six weeks and twelve months before the study's baseline and end-line surveys.\n\nExclusion Criteria:\n\n* Women whose births resulted in a loss,\n* Women who do consent to participate in the surveys\n* Women who face a language barrier with surveyors will not be enrolled.","FEMALE","15 Years","49 Years",{"count":364,"type":22},302,[81],"The study aims to assess the effectiveness of male-female VHV\u002FWs working in pairs on women's uptake of second PNC visits in rural Sepone, Lao PDR.\n\nMethods A quasi-experimental cluster study will be conducted between July 2024 and October 2026 in 37 selected sites from two districts in southern Lao PDR. In 19 selected intervention villages in the Sepone district, female-male VHV\u002FWs pairs will promote postpartum services, whereas, in 18 similar control villages in the Vilabuly district, VHV\u002FWs will work as individuals.",[368,369],"Pregnant Women","Lactating Mother","2024-10-23",{"date":372,"type":31},"2024-10-28",{"date":374,"type":31},"2024-08-10",{"date":376,"type":22},"2026-10-31",{"name":378,"class":38},"University of the Ryukyus",""]